Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case 22% Improvement Relative Risk HCQ for COVID-19  Datta et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 281 patients in India Fewer cases with HCQ (not stat. sig., p=0.47) c19hcq.org Datta et al., J. Vaccines & Vaccinatio.., Nov 2020 Favors HCQ Favors control

No Role of HCQ in COVID-19 Prophylaxis: A Survey amongst Indian Doctors

Datta et al., Journal of Vaccines & Vaccination, S6:1000002
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Survey of Indian doctors not finding a significant effect of HCQ prophylaxis.
Although the 22% fewer cases is not statistically significant, it is consistent with the significant 28% fewer cases [20‑35%] from meta analysis of the 81 cases results to date.
risk of case, 22.1% lower, RR 0.78, p = 0.47, treatment 16 of 146 (11.0%), control 19 of 135 (14.1%), NNT 32.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Datta et al., 6 Nov 2020, retrospective, India, peer-reviewed, 7 authors.
This PaperHCQAll
No Role of HCQ in COVID-19 Prophylaxis: A Survey amongst Indian Doctors
Debasis Datta, Samit Ghosal, Binayak Sinha, Sujata Datta, Twisha Chakraborty, Kalyan Kumar Gangopadhyay, Arup Ratan Dutta
The COVID-19 pandemic is being tackled on two fronts-prevention and treatment. In addition to behavioural strategies and vaccines (eagerly awaited), pharmacotherapy is also being employed in certain regions as a preventive strategy. In India, hydroxychloroquine (HCQ), ivermectin, a variety of vitamin supplements are being used, with HCQ being the most popular among healthcare professionals. In addition to the evidence-based recommendations, it is important to ascertain the situation on the ground. We conducted a multicentric survey among physicians from a wide range of specialities to ascertain the usage on HCQ and its effects of COVID-19 prevention. We did not find any significant impact of HCQ on the prevention of COVID-19 (p=0.54) independent of the duration of its usage. This pilot project has the potential to act as a backbone for a larger study exploring the impact of pharmacological intervention on COVID-19 prevention.
References
Alhazzani, Møller, Arabi, Loeb, Gong, Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19), Intensive Care Med
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19, N Engl J Med
Hernandez, Roman, Pasupuleti, Barboza, White, Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19, Ann Intern Med
Infante, Ricordi, Caprio, Fabbri, Hydroxychloroquine in the COVID-19 pandemic era: In pursuit of a rational use for prophylaxis of SARS-CoV-2 infection, Expert Rev Anti Infect Ther
Rajasingham, Bangdiwala, Nicol, Skipper, Pastick et al., Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: A randomized trial, Med Rxiv
Salunke, Thivari, Pandey, Nandy, Ratna et al., No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes & Metabolic Syndrome, Clin Res & Reviews
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit